<DOC>
	<DOCNO>NCT01144702</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness fix combination artesunate+mefloquine treatment uncomplicated malaria cause Plasmodium falciparum municipality Cruzeiro Sul , Juruá Valley , Brazil , use specific first-line drug .</brief_summary>
	<brief_title>Effectiveness Association Artesunate Mefloquine Treatment Malaria Plasmodium Falciparum</brief_title>
	<detailed_description>- Objectives : To evaluate efficacy fix combination artesunate + mefloquine treatment uncomplicated malaria cause Plasmodium falciparum , county ( municipality ) Cruzeiro Sul , Juruá Valley , State Acre ( AC ) , Brazil , use specific first-line drug . - Selection Criteria : Persons age 6 month 70 year history fever last 48 hour confirm diagnosis mono-infection Plasmodium falciparum ( F F+Fg ) parasitemia 250 100000 parasites/μl absence sign severe malaria , malnutrition another severe disease . Pregnant woman include . - Intervention : Three day supervise treatment fix combination artesunate+mefloquine ( ASMQ-Farmanguinhos/Fiocruz ) accordance scheme recommend Ministry Health , respect four age weight group base target dose drug ( artesunate -4 mg/kg/dose 12 mg/kg total dose , mefloquine- 8 mg/kg/dose 24 mg/kg total dose ) . Patients range 5 &lt; 18 kg ( 6 month 5 year old ) receive combination pediatric presentation ( ASMQ 25 + 50mg ) subject 18 kg ( 6 year year old ) receive presentation ASMQ 100 + 200mg . - Main Outcomes : The proportion subject experienced treatment failure follow 42 day use estimate effectiveness antimalarial combination study . Adverse event speed resolution clinical infectious status describe . The phenotype multidrug resistance ( MDR ) investigate population P. falciparum present subject study . - Methods : A therapeutic trial single `` arm '' prospective evaluation clinical parasitological response least 100 individual uncomplicated malaria P. falciparum treat artesunate+mefloquine combination three day monitor 42 day . The follow-up do assessment first four day week day 42 . During visit , subject submit interview , clinical examination , temperature measurement collection venous ( D0 , D3 D42 ) capillar ( visit ) blood sample hemogram ( D0 , D3 D42 ) parasitological exam ( visit ) . The parasitological evaluation do microscopy ( immediately review later ) real time PCR ( qPCR ) order confirm infect specie Plasmodium , detect gametocyte measure parasitemia ( parasites/μl ) . ) . The blood sample D0 ( treatment ) use evaluate phenotype multidrug resistance ( MDR ) population P. falciparum . - Potential risk participant : The action propose add risk beyond inherent treatment course illness , since fix combination artesunate + mefloquine use first line treatment uncomplicated malaria cause Plasmodium falciparum Valley Juruá since 2006 still recognize Ministry Health alternative combination artemether + lumefantrine Brazil . If necessary , study subject could admit General Hospital Juruá seat outpatient malaria . Medical laboratory support guarantee free charge study subject health problem present follow-up . - What study add knowledge public health ? : This study offer crucial knowledge guide development policy antimalarial drug endemic area .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Be age 6 month 70 year old ; Be monoinfection confirm laboratorial P.falciparum ; Having parasite count 250/µl 100000/µl ; If female , pregnant , confirm specific test ; Being feverish report fever ( axillary temperature &gt; 37.5°C 99,5°F ) last 48 hour ; Be able receive oral medication ; Demonstrate interest facility meet schedule visit monitor 42 day ; Agree participate study signature ( parent ) Consent Term ; Do show evidence severe malnutrition : underweight 60 % weightstandard , belowaverage height age indicate malnutrition past weightheight average indicate dietary current deficiency ( WHO , 2006 ) ; Do show danger signal severe malaria . Note : We careful include individual use quinine quinidine recently ( three day ) , risk toxicity due interaction mefloquine . Present inclusion , danger signs/symptoms severe malaria recommend WHO ; Present inclusion , laboratory evidence mixed infection another specie Plasmodium ; Having diagnosis acute infectious disease course fever , acute respiratory infection , common virus childhood diarrhea , etc ; Having diagnosis chronic co morbidity severe disease cirrhosis , chronic renal failure heart failure ; Have history hypersensitivity component combination ASMQ .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>artesunate mefloquine combination ( ASMQ )</keyword>
	<keyword>treatment</keyword>
	<keyword>Juruá Valley</keyword>
	<keyword>Brazil</keyword>
	<keyword>multidrug resistance 1 gene Plasmodium falciparum -Pfmdr1</keyword>
</DOC>